Inductive Bio

Inductive Bio is an AI-powered virtual lab for small molecule drug discovery, based in New York and founded in 2022 by Josh Haimson and Ben Birnbaum (both formerly of Flatiron Health). The company pairs medicinal chemists with machine learning to run millions of in silico ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) experiments, surface the strongest compound hypotheses, and accelerate the path to development candidates. Its Beacon-1 models took first place in both the 2025 Polaris/ASAP and 2026 OpenADMET/ExpansionRx blind ADMET competitions, and are delivered through the Compass software platform (with the Indy AI chemistry assistant) and an Embedded Experts services offering. Inductive Bio operates a pre-competitive ADMET data consortium, is SOC 2 compliant, and is backed by a16z, Lux Capital, Bessemer Venture Partners, Obvious Ventures, Character, and S32. Compass is enterprise/partner software; it exposes an API to partner teams but publishes no public, self-serve developer portal, OpenAPI, or SDK.

Inductive Bio is profiled on the APIs.io network. Tagged areas include Company, Drug Discovery, Machine Learning, Artificial Intelligence, and ADMET.

Inductive Bio’s developer surface includes engineering blog, signup flow, and 7 more developer resources.

🌐 Visit website 📡 Source on GitHub

15.5/100 emerging ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyDrug DiscoveryMachine LearningArtificial IntelligenceADMETSmall MoleculeComputational ChemistryLife SciencesBiotechPharmaceuticals

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 15.5/100 · emerging

Contract Quality 0.0 / 25

Developer Ergonomics 0.4 / 20

Commercial Clarity 4.2 / 20

Operational Transparency 0.7 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/inductive-bio: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Get Started 2

Portal, sign-up, and the first successful call

Login

SignUp

SignUp

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt

LLMsTxt

Design & Contract 1

Pagination, idempotency, versioning, errors, and events

Conformance

Conformance

Build 1

SDKs, sample code, and the tooling you integrate with

GitHubOrganization

GitHubOrganization

Access & Security 2

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Compliance

Compliance

Company 2

The organization behind the API

Website

Website

Blog

Blog

Source (apis.yml)

aid: inductive-bio
name: Inductive Bio
description: Inductive Bio is an AI-powered virtual lab for small molecule drug discovery, based in New York and founded in
  2022 by Josh Haimson and Ben Birnbaum (both formerly of Flatiron Health). The company pairs medicinal chemists with machine
  learning to run millions of in silico ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) experiments, surface
  the strongest compound hypotheses, and accelerate the path to development candidates. Its Beacon-1 models took first place
  in both the 2025 Polaris/ASAP and 2026 OpenADMET/ExpansionRx blind ADMET competitions, and are delivered through the Compass
  software platform (with the Indy AI chemistry assistant) and an Embedded Experts services offering. Inductive Bio operates
  a pre-competitive ADMET data consortium, is SOC 2 compliant, and is backed by a16z, Lux Capital, Bessemer Venture Partners,
  Obvious Ventures, Character, and S32. Compass is enterprise/partner software; it exposes an API to partner teams but publishes
  no public, self-serve developer portal, OpenAPI, or SDK.
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://www.inductive.bio/favicon.ico
url: https://raw.githubusercontent.com/api-evangelist/inductive-bio/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- a16z
- lux-capital
- bessemer-venture-partners
- obvious-ventures
- character
- s32
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Drug Discovery
- Machine Learning
- Artificial Intelligence
- ADMET
- Small Molecule
- Computational Chemistry
- Life Sciences
- Biotech
- Pharmaceuticals
apis: []
common:
- type: DomainSecurity
  url: security/inductive-bio-domain-security.yml
- type: Website
  url: https://www.inductive.bio/
- type: Blog
  url: https://www.inductive.bio/blog
- type: GitHubOrganization
  url: https://github.com/inductive-bio
- type: Login
  url: https://app.inductive.bio/login
- type: SignUp
  url: https://www.inductive.bio/book-a-demo
- type: LLMsTxt
  url: llms/inductive-bio-llms.txt
- type: Conformance
  url: conformance/inductive-bio-conformance.yml
- type: Compliance
  url: conformance/inductive-bio-conformance.yml
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence